Login to Your Account

Financings Roundup

Antibody Firm KaloBios Enters IPO Queue, Aims to Raise $60M

By Marie Powers
Staff Writer

Monday, October 8, 2012
On Friday, monoclonal antibody (mAb) developer KaloBios Pharmaceuticals Inc. filed a registration statement with the SEC for a proposed initial public offering (IPO), indicating a proposed maximum offering price of $60 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription